Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors
Abstract Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FD...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Cancer Imaging |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40644-022-00512-z |
| _version_ | 1797977295145664512 |
|---|---|
| author | E. Lopci N. Aide A. Dimitrakopoulou-Strauss L. Dercle A. Iravani R. D. Seban C. Sachpekidis O. Humbert O. Gheysens A. W. J. M. Glaudemans W. A. Weber A. D. Van den Abbeele R. L. Wahl A. M. Scott N. Pandit-Taskar R. J. Hicks |
| author_facet | E. Lopci N. Aide A. Dimitrakopoulou-Strauss L. Dercle A. Iravani R. D. Seban C. Sachpekidis O. Humbert O. Gheysens A. W. J. M. Glaudemans W. A. Weber A. D. Van den Abbeele R. L. Wahl A. M. Scott N. Pandit-Taskar R. J. Hicks |
| author_sort | E. Lopci |
| collection | DOAJ |
| description | Abstract Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published “Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [ 18 F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0”. These recommendations arose from a fruitful collaboration between international nuclear medicine societies and experts in cancer treatment. In this perspective, the key elements of the initiative are reported, summarizing the core aspects of the guidelines for radiologists and nuclear medicine physicians. Beyond the previous guidelines, this perspective adds further commentary on how this technology can advance development of novel therapeutic approaches and guide management of individual patients. |
| first_indexed | 2024-04-11T05:04:36Z |
| format | Article |
| id | doaj.art-c96e88f188af49569f27582b906b77e7 |
| institution | Directory Open Access Journal |
| issn | 1470-7330 |
| language | English |
| last_indexed | 2024-04-11T05:04:36Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Imaging |
| spelling | doaj.art-c96e88f188af49569f27582b906b77e72022-12-25T12:27:42ZengBMCCancer Imaging1470-73302022-12-012211510.1186/s40644-022-00512-zPerspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumorsE. Lopci0N. Aide1A. Dimitrakopoulou-Strauss2L. Dercle3A. Iravani4R. D. Seban5C. Sachpekidis6O. Humbert7O. Gheysens8A. W. J. M. Glaudemans9W. A. Weber10A. D. Van den Abbeele11R. L. Wahl12A. M. Scott13N. Pandit-Taskar14R. J. Hicks15Nuclear Medicine Unit, IRCCS – Humanitas Research HospitalNuclear Medicine Department, University HospitalClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ)Department of Radiology, New York Presbyterian, Columbia University Irving Medical CenterDepartment of Radiology, The University of WashingtonDepartment of Nuclear Medicine and Endocrine Oncology, Institut CurieClinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ)Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d’AzurDepartment of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain)Nuclear Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center GroningenDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University MunichDepartment of Imaging, Dana-Farber Cancer Institute and Department of Radiology, Mass General Brigham Hospitals, Harvard Medical SchoolMallinckrodt Institute of Radiology, Washington University School of MedicineDepartment of Molecular Imaging and Therapy, Austin HealthMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan-Kettering Cancer CenterThe Department of Medicine, St Vincent’s Medical School, the University of MelbourneAbstract Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published “Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [ 18 F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0”. These recommendations arose from a fruitful collaboration between international nuclear medicine societies and experts in cancer treatment. In this perspective, the key elements of the initiative are reported, summarizing the core aspects of the guidelines for radiologists and nuclear medicine physicians. Beyond the previous guidelines, this perspective adds further commentary on how this technology can advance development of novel therapeutic approaches and guide management of individual patients.https://doi.org/10.1186/s40644-022-00512-zPositron emission tomographyPET/CT[18F]FDGGuidelineImmunotherapyTreatment response |
| spellingShingle | E. Lopci N. Aide A. Dimitrakopoulou-Strauss L. Dercle A. Iravani R. D. Seban C. Sachpekidis O. Humbert O. Gheysens A. W. J. M. Glaudemans W. A. Weber A. D. Van den Abbeele R. L. Wahl A. M. Scott N. Pandit-Taskar R. J. Hicks Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors Cancer Imaging Positron emission tomography PET/CT [18F]FDG Guideline Immunotherapy Treatment response |
| title | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors |
| title_full | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors |
| title_fullStr | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors |
| title_full_unstemmed | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors |
| title_short | Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors |
| title_sort | perspectives on joint eanm snmmi anzsnm practice guidelines procedure standards for 18f fdg pet ct imaging during immunomodulatory treatments in patients with solid tumors |
| topic | Positron emission tomography PET/CT [18F]FDG Guideline Immunotherapy Treatment response |
| url | https://doi.org/10.1186/s40644-022-00512-z |
| work_keys_str_mv | AT elopci perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT naide perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT adimitrakopouloustrauss perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT ldercle perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT airavani perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT rdseban perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT csachpekidis perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT ohumbert perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT ogheysens perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT awjmglaudemans perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT waweber perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT advandenabbeele perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT rlwahl perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT amscott perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT npandittaskar perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors AT rjhicks perspectivesonjointeanmsnmmianzsnmpracticeguidelinesprocedurestandardsfor18ffdgpetctimagingduringimmunomodulatorytreatmentsinpatientswithsolidtumors |